CRSP Aiming for $44-49 First Target- Currently in shares.I am looking at my Algos, and Oscillators timed up with support and resistance lines showing a pretty clear breakout of the beatdown that CRSP has been getting. Cheers!
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.8 USD
−153.61 M USD
371.21 M USD
81.70 M
About CRISPR Therapeutics AG
Sector
Industry
CEO
Samarth Kulkarni
Website
Headquarters
Zug
Founded
2013
ISIN
CH0334081137
FIGI
BBG00JSC0TQ9
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
$CRSP: A BioTech to add to the watchlist! 95% UpsideNASDAQ:CRSP
Not a High Five Setup...yet
-H5 Indicator is GREEN
-Filling Volume Profile GAP and setting up at a new Volume Profile Shelf
-Need Wr% to push up above -20 and form Williams Consolidation Box
-Need to breakout of Symmetrical Triangle at $56ish
If we get that it will be a H5 Trade and
Looking for the next Amazon or Tesla to invest at the Start?CRISPR Therapeutics - revenue projection = Massive
I am accumulating shares. you may want to start looking into CrSp.Let's calculate the revenue potential for CRISPR Therapeutics based on their approved therapy and pipeline:
THERAPY 1: BEING ROLLED OUT AND APPROVED IN THE USA AND EUROPE
Casgevy (
Cound this be ? and yet maybe is will.....CRISPR Therapeutics - the next Trillion Dollar Company.
November 14, 2024
Investing ins SpaceX before it goes Public.... This is good advice !!! Space is the new War Economy, I mead the defense machine needs a new business line, and space is more profitable than any war economy X 50 - war economy
4 hour bullish divergence It was pointed out to me earlier that the last time I posted was back in May so I thought I’d pull my finger out and share this one.
The company has developed a cure for sickle cell disease, by gene editing, this disease is seriously debilitating and affects millions of people of African descent, t
CRSPR 72824I am looking to start a dca campaign here. I see value at the 50 level. I have no clue where its going short/mid term. Over the long term i see it continuing its upward march. Looks very bullish over the long term.
CRSP: This company is losing moneyNot only are they losing money they took out a bunch of high interest debt. They're going to start hemorrhaging. However long it takes, they're going to the single digits in stock price.
CRSP | Time to Start Accumulating | LONGCRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. T
CRSPBought today, got a nice move.
Published earlier this idea on X
Getting an extension, I am trading this impulse up only
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0VRQ is 40.0 USD — it has decreased by −0.81% in the past 24 hours. Watch CRISPR THERAPEUTICS AG COM CHF0.03 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange CRISPR THERAPEUTICS AG COM CHF0.03 stocks are traded under the ticker 0VRQ.
0VRQ stock has fallen by −10.46% compared to the previous week, the month change is a −13.61% fall, over the last year CRISPR THERAPEUTICS AG COM CHF0.03 has showed a −34.47% decrease.
We've gathered analysts' opinions on CRISPR THERAPEUTICS AG COM CHF0.03 future price: according to them, 0VRQ price has a max estimate of 199.00 USD and a min estimate of 30.00 USD. Watch 0VRQ chart and read a more detailed CRISPR THERAPEUTICS AG COM CHF0.03 stock forecast: see what analysts think of CRISPR THERAPEUTICS AG COM CHF0.03 and suggest that you do with its stocks.
0VRQ reached its all-time high on Jan 15, 2021 with the price of 216.6 USD, and its all-time low was 14.2 USD and was reached on Dec 16, 2021. View more price dynamics on 0VRQ chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0VRQ stock is 2.56% volatile and has beta coefficient of 1.75. Track CRISPR THERAPEUTICS AG COM CHF0.03 stock price on the chart and check out the list of the most volatile stocks — is CRISPR THERAPEUTICS AG COM CHF0.03 there?
Today CRISPR THERAPEUTICS AG COM CHF0.03 has the market capitalization of 3.49 B, it has decreased by −9.30% over the last week.
Yes, you can track CRISPR THERAPEUTICS AG COM CHF0.03 financials in yearly and quarterly reports right on TradingView.
CRISPR THERAPEUTICS AG COM CHF0.03 is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
0VRQ earnings for the last quarter are −1.01 USD per share, whereas the estimation was −1.38 USD resulting in a 27.06% surprise. The estimated earnings for the next quarter are −1.22 USD per share. See more details about CRISPR THERAPEUTICS AG COM CHF0.03 earnings.
CRISPR THERAPEUTICS AG COM CHF0.03 revenue for the last quarter amounts to 602.00 K USD, despite the estimated figure of 6.57 M USD. In the next quarter, revenue is expected to reach 7.63 M USD.
0VRQ net income for the last quarter is −85.94 M USD, while the quarter before that showed −126.41 M USD of net income which accounts for 32.01% change. Track more CRISPR THERAPEUTICS AG COM CHF0.03 financial stats to get the full picture.
No, 0VRQ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 407.00 employees. See our rating of the largest employees — is CRISPR THERAPEUTICS AG COM CHF0.03 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CRISPR THERAPEUTICS AG COM CHF0.03 EBITDA is −313.02 M USD, and current EBITDA margin is −54.61%. See more stats in CRISPR THERAPEUTICS AG COM CHF0.03 financial statements.
Like other stocks, 0VRQ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CRISPR THERAPEUTICS AG COM CHF0.03 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CRISPR THERAPEUTICS AG COM CHF0.03 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CRISPR THERAPEUTICS AG COM CHF0.03 stock shows the strong sell signal. See more of CRISPR THERAPEUTICS AG COM CHF0.03 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.